[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

AR020287A1 - Preparaciones de una combinacion farmaceutica. - Google Patents

Preparaciones de una combinacion farmaceutica.

Info

Publication number
AR020287A1
AR020287A1 ARP990105974A ARP990105974A AR020287A1 AR 020287 A1 AR020287 A1 AR 020287A1 AR P990105974 A ARP990105974 A AR P990105974A AR P990105974 A ARP990105974 A AR P990105974A AR 020287 A1 AR020287 A1 AR 020287A1
Authority
AR
Argentina
Prior art keywords
pharmaceutical combination
preparations
pharmaceutically acceptable
acceptable salt
heart
Prior art date
Application number
ARP990105974A
Other languages
English (en)
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8233041&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR020287(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of AR020287A1 publication Critical patent/AR020287A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Una preparacion de una combinacion farmacéutica para el tratamiento de trastornos cardíacos y cardiovasculares tales como hipertension, angina de pecho,insuficiencia cardíaca y enfermedades relacionadas, que contiene las sustancias activas carvedilolo una sal farmacéuticamente aceptable del mismo ehidroclorotiazida o una sal farmacéuticamente aceptable de la misma, así como aditivos usuales farmacéuticamente.
ARP990105974A 1998-11-27 1999-11-24 Preparaciones de una combinacion farmaceutica. AR020287A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP98122489 1998-11-27

Publications (1)

Publication Number Publication Date
AR020287A1 true AR020287A1 (es) 2002-05-02

Family

ID=8233041

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP990105974A AR020287A1 (es) 1998-11-27 1999-11-24 Preparaciones de una combinacion farmaceutica.

Country Status (22)

Country Link
US (3) US6403579B1 (es)
EP (1) EP1131072B1 (es)
JP (2) JP2002531395A (es)
KR (1) KR100421347B1 (es)
CN (1) CN1184971C (es)
AR (1) AR020287A1 (es)
AT (1) ATE238056T1 (es)
AU (1) AU765977B2 (es)
BR (1) BR9915610A (es)
CA (1) CA2352361C (es)
CO (1) CO5011053A1 (es)
DE (1) DE69907252T2 (es)
DK (1) DK1131072T3 (es)
ES (1) ES2195638T3 (es)
MY (1) MY121831A (es)
PE (1) PE20001302A1 (es)
PT (1) PT1131072E (es)
TR (3) TR200101470T2 (es)
TW (1) TWI228414B (es)
UY (1) UY25821A1 (es)
WO (1) WO2000032174A2 (es)
ZA (1) ZA200104280B (es)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20001302A1 (es) * 1998-11-27 2000-11-30 Hoffmann La Roche Preparaciones de una combinacion farmaceutica que contiene carvedilol e hidroclorotiazida
JP2004518734A (ja) * 2000-10-24 2004-06-24 スミスクライン・ビーチャム・コーポレイション カルベジロールの新規処方
US20030070584A1 (en) 2001-05-15 2003-04-17 Cynthia Gulian Dip coating compositions containing cellulose ethers
IN191028B (es) * 2001-05-17 2003-09-13 Sun Pharmaceutical Ind Ltd
US8309118B2 (en) 2001-09-28 2012-11-13 Mcneil-Ppc, Inc. Film forming compositions containing sucralose
US8101209B2 (en) 2001-10-09 2012-01-24 Flamel Technologies Microparticulate oral galenical form for the delayed and controlled release of pharmaceutical active principles
JP2006500320A (ja) * 2002-04-30 2006-01-05 エスビー・ファルムコ・プエルト・リコ・インコーポレイテッド カルベジロール一クエン酸塩一水和物
WO2004002472A1 (en) 2002-06-27 2004-01-08 Sb Pharmco Puerto Rico Inc. Carvedilol hydrobromide
CN1678305A (zh) 2002-06-27 2005-10-05 Sb药物波多黎各公司 卡维地洛磷酸盐和/或其溶剂合物和/或相应组合物和/或治疗方法
AU2003275953A1 (en) 2002-11-08 2004-06-07 Egalet A/S Controlled release carvedilol compositions
EP1610767B1 (en) 2003-03-26 2011-01-19 Egalet A/S Morphine controlled release system
WO2004094378A1 (en) * 2003-04-21 2004-11-04 Matrix Laboratories Ltd Process for the preparation of carvedilol form-ii
WO2005030201A1 (fr) * 2003-09-26 2005-04-07 Shuyi Zhang Preparation a liberation prolongee contenant de l'hydrochlorothiazide et du carvedilol/atenolol
ES2662903T3 (es) * 2003-11-25 2018-04-10 Smithkline Beecham (Cork) Limited Base libre de carvedilol, sales, formas anhidras o solvato de la misma, composiciones farmacéuticas correspondientes, formulaciones de liberación controlada, y procedimientos de tratamiento o administración
US7750036B2 (en) 2003-11-25 2010-07-06 Sb Pharmco Puerto Rico Inc. Carvedilol salts, corresponding compositions, methods of delivery and/or treatment
JP2007512350A (ja) * 2003-11-25 2007-05-17 エスビー・ファルムコ・プエルト・リコ・インコーポレイテッド カルベジロール組成物の治療および送達方法
ATE358478T1 (de) * 2003-12-02 2007-04-15 Nicox Sa Nitrooxy-derivate von carvedilol und anderen betablockern als antihypertensiva
EP2281556A1 (en) * 2005-02-25 2011-02-09 F. Hoffmann-La Roche AG Tablets with improved drugs substance dispersibility
CA2654890C (en) * 2006-06-16 2015-10-06 Lek Pharmaceuticals D.D. Pharmaceutical composition
GB0612540D0 (en) * 2006-06-23 2006-08-02 Novartis Ag Galenical formulations of organic compounds
WO2008114276A1 (en) * 2007-03-16 2008-09-25 Lupin Limited Novel oral controlled release composition of carvedilol
US8821928B2 (en) 2007-06-04 2014-09-02 Egalet Ltd. Controlled release pharmaceutical compositions for prolonged effect
EP2393484A1 (en) 2009-02-06 2011-12-14 Egalet Ltd. Immediate release composition resistant to abuse by intake of alcohol
CA2766179A1 (en) 2009-06-24 2010-12-29 Egalet Ltd. Controlled release formulations
EP2544723A2 (en) * 2010-03-10 2013-01-16 Giuliani International Limited Compositions for colon lavage and methods of making and using same

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2815926A1 (de) 1978-04-13 1979-10-18 Boehringer Mannheim Gmbh Neue carbazolyl-(4)-oxy-propanolamin-derivate, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel
FR2643556B1 (fr) * 1989-02-27 1993-03-05 Sanofi Sa Composition pharmaceutique a liberation prolongee d'acide valproique
ATE133068T1 (de) * 1991-01-30 1996-02-15 Wellcome Found Wasserlösliche tabletten
EP0546593B1 (en) * 1991-10-30 1997-09-03 Glaxo Group Limited Multi-layered compositions containing histamine or serotonin antagonists
TW483763B (en) * 1994-09-02 2002-04-21 Astra Ab Pharmaceutical composition comprising of ramipril and dihydropyridine compound
US5760069A (en) * 1995-02-08 1998-06-02 Boehringer Mannheim Pharmaceuticals Corporation-Smithkline Beecham Corporation Limited Partnership #1 Method of treatment for decreasing mortality resulting from congestive heart failure
FR2752162B1 (fr) * 1996-08-07 1998-11-06 Jouveinal Lab Comprime de maleate de trimebutine pellicule
DE19637082A1 (de) * 1996-09-12 1998-03-19 Boehringer Mannheim Gmbh Schnellzerfallende Pellets
PE20001302A1 (es) * 1998-11-27 2000-11-30 Hoffmann La Roche Preparaciones de una combinacion farmaceutica que contiene carvedilol e hidroclorotiazida

Also Published As

Publication number Publication date
MY121831A (en) 2006-02-28
KR20010080578A (ko) 2001-08-22
CN1328460A (zh) 2001-12-26
WO2000032174A2 (en) 2000-06-08
TR200200981T2 (tr) 2002-06-21
US20040087578A1 (en) 2004-05-06
DK1131072T3 (da) 2003-08-11
BR9915610A (pt) 2001-08-14
ES2195638T3 (es) 2003-12-01
TR200101470T2 (tr) 2001-11-21
AU1506500A (en) 2000-06-19
TR200200982T2 (tr) 2002-06-21
CA2352361C (en) 2007-01-02
CO5011053A1 (es) 2001-02-28
AU765977B2 (en) 2003-10-09
PT1131072E (pt) 2003-08-29
UY25821A1 (es) 2001-07-31
JP2002531395A (ja) 2002-09-24
KR100421347B1 (ko) 2004-03-06
US20020052367A1 (en) 2002-05-02
EP1131072B1 (en) 2003-04-23
ZA200104280B (en) 2002-08-26
EP1131072A2 (en) 2001-09-12
CA2352361A1 (en) 2000-06-08
WO2000032174A3 (en) 2000-11-16
DE69907252D1 (de) 2003-05-28
JP2007077160A (ja) 2007-03-29
ATE238056T1 (de) 2003-05-15
CN1184971C (zh) 2005-01-19
DE69907252T2 (de) 2004-01-29
TWI228414B (en) 2005-03-01
PE20001302A1 (es) 2000-11-30
US6403579B1 (en) 2002-06-11

Similar Documents

Publication Publication Date Title
AR020287A1 (es) Preparaciones de una combinacion farmaceutica.
AR012269A1 (es) COMPOSICIoN FARMACÉUTICA Y USO DE LA MISMA PARA LA FABRICACIoN DE MEDICAMENTOS
BG104075A (en) Combined treatment including atorvastatin and an antihypertonic form
ES2175127T3 (es) Derivados de la quinazolina y su uso.
CR8258A (es) Derivados de azepine como agentes farmaceuticos
AR026610A1 (es) Un derivado pirrolidinacetamida solo o en combinacion para tratamiento de desordenes del sistema nervioso central
EA200300155A1 (ru) Терапевтическая комбинация ингибитора сетр и аторвастатина
AR029825A1 (es) Una composicion farmaceuticamente aceptable que comprende carvedilol o una sal del mismo farmaceuticamente aceptable, un procedimiento para la produccion de dicha composicion y utilizacion de la misma
PT951474E (pt) Novos derivados da ciclosporina sua preparacao e composicoes farmaceuticas que os contem
HUP0104718A2 (hu) Mikronizált eplerenon kompozíciók és eljárás az előállításukra
UY26372A1 (es) "imidazo-3-il-aminas bicíclicas procedimiento para su preparación y medicamentos que las contienen "
EE05287B1 (et) Tsklopentanoindoolid, nende kasutamine ravimi valmistamiseks ning neid sisaldav farmatseutiline kompositsioon
NO20043101L (no) Farmasoytiske blandinger av oralt aktive taxanderivater som har forsterket biotilgjenglighet
ECSP083351A (es) Composiciones farmacéuticas
PA8457201A1 (es) Terapias de combinacion
CL2008003941A1 (es) Uso de escitalopram o de una sal farmaceuticamente aceptable del mismo para preparar un medicamento util en el tratamiento del desorden compulsivo obsesivo.
AR032293A1 (es) Estuche farmaceutico
ES2045182T3 (es) Substancias fisiologicamente activas, un proceso para la preparacion de las mismas y composiciones farmaceuticas que las contienen.
ECSP024389A (es) Composiciones farmaceuticas solidas de valsartan
BR9916575A (pt) Composição farmacêutica de liberação controlada com mesilato de tilidina como substância-ativa
AR023687A1 (es) Una composicion para el tratamiento de desordenes de la retina externa y el uso de un antagonista de glutamato para la manufactura de un medicamento parael tratamiento de desordenes de la retina externa
HN2000000075A (es) Profarmacos mutuos amlodipino y atorvastatina
ES2175827T3 (es) Formulaciones transmucosas de levosimendano.
AR037496A1 (es) Uso novedoso del 2-[5-(4-fluorofenil)-3-piridilmetilaminometil]-cromano y sus sales fisiologicamente aceptables
ECSP993240A (es) Preparaciones de combinacion farmaceutica

Legal Events

Date Code Title Description
FB Suspension of granting procedure